Alemtuzumab 0.2 mg ( DrugBank: Alemtuzumab )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
65	原発性免疫不全症候群	1
164	眼皮膚白皮症	1

65. 原発性免疫不全症候群

臨床試験数 : 482 / 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01652092 (ClinicalTrials.gov)	September 4, 2012	25/7/2012	Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies	Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies	SCID;Omenn's Syndrome;Reticular Dysgenesis;Wiskott-Aldrich Syndrome;Bare Lymphocyte Syndrome;Common Variable Immunodeficiency;Chronic Granulomatous Disease;CD40 Ligand Deficiency;Hyper IgM Syndrome;X-linked Lymphoproliferative Disease;Hemophagocytic Lymphohistiocytosis;Griscelli Syndrome;Chediak-Higashi Syndrome;Langerhan's Cell Histiocytosis	Drug: Alemtuzumab 0.3 mg;Drug: Cyclophosphamide;Drug: Busulfan;Biological: Stem Cell Transplantation;Drug: Fludarabine phosphate 40 mg;Drug: Melphalan;Drug: Alemtuzumab 0.2 mg;Drug: Fludarabine phosphate 30 mg;Drug: MESNA	Masonic Cancer Center, University of Minnesota	NULL	Recruiting	N/A	50 Years	All	30	N/A	United States

164. 眼皮膚白皮症

臨床試験数 : 15 / 薬物数 : 57 - (DrugBank : 34) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 139

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01652092 (ClinicalTrials.gov)	September 4, 2012	25/7/2012	Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies	Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies	SCID;Omenn's Syndrome;Reticular Dysgenesis;Wiskott-Aldrich Syndrome;Bare Lymphocyte Syndrome;Common Variable Immunodeficiency;Chronic Granulomatous Disease;CD40 Ligand Deficiency;Hyper IgM Syndrome;X-linked Lymphoproliferative Disease;Hemophagocytic Lymphohistiocytosis;Griscelli Syndrome;Chediak-Higashi Syndrome;Langerhan's Cell Histiocytosis	Drug: Alemtuzumab 0.3 mg;Drug: Cyclophosphamide;Drug: Busulfan;Biological: Stem Cell Transplantation;Drug: Fludarabine phosphate 40 mg;Drug: Melphalan;Drug: Alemtuzumab 0.2 mg;Drug: Fludarabine phosphate 30 mg;Drug: MESNA	Masonic Cancer Center, University of Minnesota	NULL	Recruiting	N/A	50 Years	All	30	N/A	United States